Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Lymphoma

 

Rituximab + Lenalidomide vs Chemotherapy (RELEVANCE-7636)
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma. The "RELEVANCE" Trial (Rituximab Lenalidomide Versus Any Chemotherapy)

Investigator: Edward N. Libby, MD;   Conditions: Follicular Lymphoma;    Status: Recruiting;   Study ID: NCT01476787

PF-04449913 for Hematologic Malignancies (UW09021)
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies

Investigator: Vivian Oehler, M.D,;   Conditions: Hematologic Malignancies;    Status: Closed;   Study ID: NCT00953758

Pralatrexate + Chemotherapy for Non-Hodgkin's Lymphoma (FH 7860)
A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Investigator: Andrei R. Shustov, MD;   Conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma;    Status: Pending;   Study ID: NCT01336933

Zevalin for Newly Diagnosed Diffuse Large B-cell Lymphoma (FH 7779)
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy (SPI-ZEV-11-301)

Investigator: Ajay K. Gopal, MD;   Conditions: Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma;    Status: Recruiting;   Study ID: NCT01510184

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (FH 6914)
A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy

Investigator: Andrei Shustov, MD;   Conditions: Cutaneous T-cell Non-Hodgkin Lymphoma;    Status: Recruiting;   Study ID: NCT00958074

Chemo Based on PET Scan for Stage I-II Hodgkin Lymphoma (CTSU C50604)
Phase II Trial Of Response-Adapted Chemotherapy Based On Positron Emission Tomography For Non-Bulky Stage I And II Hodgkin Lymphoma

Investigator: Fred Appelbaum, MD;   Conditions: Hodgkin's Lymphoma;    Status: Closed;   Study ID: NCT01132807

Vorinostat and Combination Chemotherapy With Rituximab for HIV-Related Lymphoma (FH 2483)
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma

Investigator: Ann Woolfrey, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT01193842

Ofatumumab and Bortezomib for Waldenstrom Macroglobulinemia (FH 7574)
A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia

Investigator: Pamela S. Becker, MD;   Conditions: Waldenstrom Macroglobulinemia;    Status: Pending;   Study ID: NCT01536067

A+AVD vs. ABVD as Frontline Therapy for Hodgkin Lymphoma (UW12044)
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Investigator: Ajay K. Gopal, MD;   Conditions: Hodgkin Lymphoma;    Status: Recruiting;   Study ID: NCT01712490

PCI-32765 (Ibrutinib) + R-CHOP for Newly Diagnosed Large B-Cell Lymphoma (UW13027)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Investigator: Ajay K. Gopal, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT01855750

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide for Previously Untreated Mantle Cell Lymphoma (E1411)
Intergroup Randomized Phase 2 Four Arm Study In Patients = 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB ? R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV? R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB ? LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV ? LR)

Investigator: Brian Till, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT01415752